Page last updated: 2024-09-05

jadomycin b and ER-Negative PR-Negative HER2-Negative Breast Cancer

jadomycin b has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bennett, LG; Goralski, KB; Hall, SR; Jakeman, DL; Martinez-Farina, CF; Robertson, AW; Toulany, J	1

Other Studies

1 other study(ies) available for jadomycin b and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells. The Journal of pharmacology and experimental therapeutics, 2017, Volume: 363, Issue:2 Topics: Apoptosis; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Isoquinolines; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms	2017

Article

Year

Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.

The Journal of pharmacology and experimental therapeutics, 2017, Volume: 363, Issue:2

Topics: Apoptosis; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Isoquinolines; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms

2017